Published in:
Open Access
01-10-2018 | Original Paper
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Authors:
Alexandra Pender, Elizabeth J. Davis, Dharmisha Chauhan, Christina Messiou, Omar Al-Muderis, Khin Thway, Cyril Fisher, Shane Zaidi, Aisha Miah, Ian Judson, Winette van der Graaf, Vicki L. Keedy, Charlotte Benson, Robin L. Jones
Published in:
Medical Oncology
|
Issue 10/2018
Login to get access
Abstract
The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity and outcome data were collected. Twenty one patients were treated with gemcitabine/docetaxel, the majority as a second- or third-line treatment for metastatic disease. The response rate was 5% with a median progression-free survival of 2 months (95% CI 1.3–3.7). Toxicities reported were as expected for this chemotherapy combination. Treatment was not discontinued due to toxicity. Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not be offered to this patient group outside a clinical trial context.